JF
KTTA icon

Jump Financial’s Pasithea Therapeutics KTTA Stock Holding History

Jump Financial’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Buy
+29,363
New +$20.2K ﹤0.01% 1960

Other funds holding KTTA

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
HC
Hurley Capital New York $193M AUM 25.58% 1-Year Est. Return

Jump Financial's KTTA Position: Q2 2026 in Review

Jump Financial opened a new position in Pasithea Therapeutics (KTTA) in Q2 2026: 29,363 shares worth $15.1K. The stake represents ﹤0.01% of the portfolio and ranks #1960 among its holdings.

13 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Jump Financial held 29,363 shares of Pasithea Therapeutics worth $15.1K as of Q2 2026.
  • Pasithea Therapeutics was a new Jump Financial position in Q2 2026.
  • Pasithea Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q2 2026, its #1960 holding.
  • 13 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.